GORE VIABAHN FORTEGRA Venous Stent
W. L. Gore & Associates, Inc. · Decision date Apr 7, 2026
What did the FDA approve?
FDA records P250017/S001 as a supplement to PMA P250017, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Apr 7, 2026.
FDA approval order statement
Approval of the protocol for the new enrollment post-approval study (PAS)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 7, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P250017/S001
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QTL
- Decision code
- APPR
- Decision date
- Apr 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, vena cava.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QTL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250017. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250017 · Original PMA
GORE VIABAHN FORTEGRA Venous Stent
P250017/S001 received
Application receipt date recorded by FDA.
P250017/S002 · Related supplement
GORE VIABAHN FORTEGRA Venous Stent
P250017/S001 · FDA decision
Normal 180 Day Track No User Fee
P250017/S003 · Related supplement
GORE VIABAHN FORTEGRA Venous Stent
Timeline entries are records held by MedtechLedger for P250017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA approval | Dec 19, 2025 | FDA | |
GORE VIABAHN FORTEGRA Venous StentP250017/S002 | W. L. Gore & Associates, Inc. | PMA supplement | Mar 6, 2026 | FDA |
GORE VIABAHN FORTEGRA Venous StentP250017/S003 | W. L. Gore & Associates, Inc. | PMA supplement | Apr 30, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1505 N Fourth St., Flagstaff, AZ, 86004
Sources and methodology
- Original FDA record: P250017/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

